Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research

Apr 3, 2025
Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research

Open Wound Research and Venture Medical, LLC have entered into a collaborative research agreement to advance the study of pressure ulcer treatment. As part of this partnership, Venture Medical has acquired extensive pressure ulcer data from Open Wound Research to evaluate the efficacy of CAMPS in comparison to standard of care (SOC) treatments.

Puyallup, WA – March 11, 2025 – Open Wound Research and Venture Medical, LLC have entered into a collaborative research agreement to advance the study of pressure ulcer treatment. As part of this partnership, Venture Medical has acquired extensive pressure ulcer data from Open Wound Research to evaluate the efficacy of CAMPS in comparison to standard of care (SOC) treatments.

Pressure ulcers, also known as pressure injuries or bedsores, remain a significant healthcare challenge, particularly for patients with limited mobility. Many patients suffer from hard-to-heal pressure ulcers that do not respond to extended SOC, requiring advanced treatments or alternative modalities. This research initiative aims to provide valuable insights into how CAMPS products can improve patient outcomes by enhancing wound healing.

“We are excited to collaborate with Venture Medical as their data partner on this important research,” said Zwelithini Tunyiswa, Chief Executive Officer at Open Wound Research. “By leveraging real-world data, we aim to generate clinically relevant findings that can help shape the future management of hard-to-heal pressure ulcers.”

As part of this collaboration, Open Wound Research and Venture Medical will work with leading researchers to assess the efficacy and efficiency of CAMPS products in pressure ulcer treatment. The findings are expected to contribute to evidence-based recommendations for healthcare providers treating pressure ulcer patients.

“This collaboration marks a significant step forward in our commitment to developing and distributing advanced solutions for wound care.” said John Schroeder, Chief Executive Officer at Venture Medical. “By comparing CAMPS product performance to SOC, we seek to provide healthcare professionals with data-driven insights to optimize patient care.”

The results of this research will be shared with the medical community through publications and conferences, ensuring that clinicians and researchers have access to the latest advancements in pressure ulcer treatment.

About Venture Medical, LLC: Venture Medical is a groundbreaking healthcare services company with a decade-long history of innovation, dedication, and consistent growth in the field of wound care and healing. Over the past 15 years, Venture Medical has expanded its reach across the United States and has grown to become a leading master distributor and reseller and software services provider for manufacturers and end users of biologics, advanced diagnostics, durable medical equipment, and capital goods.

For more information, visit venturemedical1.com and follow us on LinkedIn

About Open Wound Research: Open Wound Research is committed to making wound care research simpler to conduct, reproducible, and actionable for wound care stakeholders. This is accomplished by fusing clinical, research, and data science competencies to build research and data pipelines that deliver on sponsors’ needs and vision. We are also committed to open-sourcing wound care data and software to foster transparency, participation and collaboration in wound care research.

For more information, visit openwoundresearch.com.

More News & Updates

Stay Up-To-Date With
Venture Medical

Jun 16, 2025
Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio

Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix®, along with intellectual property supporting an expected future product line. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development.

May 1, 2025
Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market

Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.

Mar 2, 2025
Alyssa Lockwood
Alyssa Lockwood
John Schroeder and Jason Matuszewski Give Presentation At CAMPS 2025

Last week at CAMPS 2025, John Schroeder, CEO of Venture Medical, and Jason Matuszewski, CEO of BioStem Technology, took the stage to deliver a compelling presentation titled “Why You Should Care About Investors in the Wound Care Space.”

Feb 28, 2025
Alyssa Lockwood
Alyssa Lockwood
Venture Medical Launches New Website!

We invite you to explore our brand new website